Tufts University School of Medicine, MaineHealth Cancer Care, 265 Western Avenue, Suite 2, South Portland, ME 04106, USA.
Hematol Oncol Clin North Am. 2021 Oct;35(5):973-990. doi: 10.1016/j.hoc.2021.05.011.
Salivary gland carcinomas are a rare and heterogenous group of cancers with varying underlying biology and clinical behavior. A quickly evolving body of data has advanced the understanding of these tumors, leading to effective therapeutics for several histologic subtypes. Biologically rational clinical trials have developed from an understanding of MYB and NOTCH signaling in adenoid cystic carcinoma. The recognition of androgen receptor signaling and HER2-targeted therapy has offered therapeutic options in non-ACC salivary cancers. The use of TRK inhibitors in salivary secretory carcinoma has led to exceptional responses. Immunotherapy is an exciting new therapeutic avenue that requires further exploration.
唾液腺癌是一组罕见且异质性的癌症，具有不同的基础生物学和临床行为。大量不断发展的数据提高了对这些肿瘤的认识，为几种组织学亚型的有效治疗提供了依据。对腺样囊性癌中 MYB 和 NOTCH 信号的理解，促成了基于生物学合理性的临床试验。对雄激素受体信号和 HER2 靶向治疗的认识，为非 ACC 唾液腺癌提供了治疗选择。TRK 抑制剂在唾液分泌性癌中的应用导致了显著的反应。免疫疗法是一个令人兴奋的新治疗途径，需要进一步探索。
